| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029210 |
| Receipt No. | R000033382 |
| Official scientific title of the study | A verification study for improving the quality of sleep by Lactobacillus brevis SBC8803 (SBL88TM) intake: A randomized double-blind, parallel-group, placebo-controlled study |
| Date of disclosure of the study information | 2017/09/20 |
| Last modified on | 2018/04/24 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | A verification study for improving the quality of sleep by Lactobacillus brevis SBC8803 (SBL88TM) intake: A randomized double-blind, parallel-group, placebo-controlled study | |
| Title of the study (Brief title) | A study for improving the quality of sleep by lactic acid bacteria SBL88TM intake | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate the effect of Lactobacillus brevis SBC8803 (SBL88TM) intake on quality of sleep. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. OSA sleep inventory MA version
*Fill it in immediately after waking up at home on the examination day and two days before |
| Key secondary outcomes | 1. Sleep test (Sleep Scan)
2. Athens Insomnia Scale (AIS) 3. Japanese version of Epworth Sleepiness Scale (JESS) 4. Beck Depression Inventory 5. Visual Analogue Scale (VAS) of subjective symptoms *1 Perform it at subject's home 1 week before screening and examination and during the test period *2-5 Assess these at 0 and 4 weeks after consuming |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | YES |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 4weeks
Test materials: Lactobacillus brevis SBC8803 (SBL88TM) sterilized lactic acid bacterial cells 25 mg (2.5 x 1010cells) Dose: Take a tablet once a day Administration: Take a tablet at optional timing. *If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_2 | Duration: 4 weeks
Test materials: Placebo Dose: Take a tablet once a day Administration: Take a tablet at optional timing. *If you forget to take the test food, take it as soon as you remember within the day. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy Japanese adults
2. Subjects who feel quality of sleep dissatisfaction 3. Subjects who are judged as eligible to participate in the study by the principal investigator 4. Subjects who are considered as appropriate for the study by the principal investigator based on the score of Beck Depression Inventory 5. Among the subjects who passed 3. and 4., subjects who have a relatively lower score of OSA sleep inventory MA version at screening and examination before ingestion |
|||
| Key exclusion criteria | 1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction
2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, sleep apnea syndrome, or other chronic diseases 3. Subjects who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily 4. Currently taking medicines (include herbal medicines) and supplements 5. Subjects who are allergic to medicines and/or the test food related products 6. Subjects who are pregnant, breast-feeding, and plan to become a pregnant 7. Subjects who live with their infants less than 1 year old 8. Subjects who co-sleep with their children (1 to 6 years old) 9. Subjects who live with requiring long-term care persons 10. Subjects who share the bed with more than one person 11. Subjects who work late-night shift and the life-styles are irregular 12. Subjects whose body mass index (BMI) is 25 kg/m2 or more 13. Subjects who wake up for urination 3 times or more during nocturnal sleep 14. Subjects whose dinner time is extremely irregular 15. Subjects who are troubled with pollen allergy or asthma 16. Subjects who drink alcohol heavily 17. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 18. Subjects who are judged as ineligible to participate in the study by the principal investigator |
|||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuo YAMAMOTO |
| Organization | ORTHOMEDICO Inc. |
| Division name | CEO |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. |
| TEL | 03-3818-0610 |
| kazu@orthomedico.jp | |
| Public contact | |
| Name of contact person | Naoko SUZUKI |
| Organization | ORTHOMEDICO Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. |
| TEL | 03-3818-0610 |
| Homepage URL | |
| nao@orthomedico.jp | |
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | SAPPORO HOLDINGS LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033382 |